Metamizole and Acute Kidney Injury (M-AKI)

29/09/2025
23/06/2026
EU PAS number:
EUPAS1000000740
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000000740

Study ID

1000000740

Official title and acronym

Metamizole and Acute Kidney Injury (M-AKI)

DARWIN EU® study

No

Study countries

Netherlands

Study description

Herein, a retrospective cohort study using electronic health records (EHR) from a major Dutch academic hospital (Amsterdam UMC) is conducted to assess the kidney safety profile of metamizole (dipyrone) use.
For this, adult inpatients (target population) who have undergone a recent surgery (postoperative setting) are selected.
The assigned treatment strategies (metamizole; active comparators: opioids, NSAIDs) are investigated to test a potential causal link between metamizole and acute kidney injury characterised by a set of predefined estimands.

Study status

Ongoing
Research institutions and networks

Institutions

Amsterdam UMC
First published:
01/02/2024
Institution Educational Institution Hospital/Clinic/Other health care facility

Contact details

Daniel Fernández Llaneza 0000-0002-2770-4214

Primary lead investigator
ORCID number:
0000-0002-2770-4214

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Other public funding (e.g. hospital or university)

More details on funding

This work was supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO; Dutch Research Council) [KICH1.ST01.20.011] and co-funded in-cash by Dutch Kidney Foundation and National Intensive Care Evaluation (NICE) foundation, and in-kind by PHARMO Institute for Drug Outcomes Research, Castor, InsightRX, Z-Index, Digital Health Link.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable